demonstrated that in patients with hematologic malignancies with reduced SARS-CoV-2 -specific antibody responses and increased COVID-19 associated mortality, a greater number of CD8+ T-lymphocytes was associated to a better outcome. This evidence concerns the gene CD8A and COVID-19.